Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2024 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
March 22, 2023 13:22 ET | Source: MacroGenics, Inc.

MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)

ROCKVILLE, MD, March 22, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for...
November 30, 2020 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
September 21, 2020 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Development Milestone Achieved in Retifanlimab (MGA012) Collaboration with Incyte

$15 Million milestone triggered by initiation of Phase 3 clinical trial in NSCLC by Incyte ROCKVILLE, MD, Sept. 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage...